The genetic test for gestational diabetes and thrombosis risk identifies genetic predispositions that may impact maternal and fetal health during pregnancy. Early detection through genetic testing enables timely intervention and preventive strategies, reducing potential complications.
Gestational diabetes is characterized by elevated blood sugar levels during pregnancy. Although it typically resolves after childbirth, it can lead to complications such as hypertension, premature birth, or increased fetal weight.
Thrombophilia is a genetic or acquired condition that increases the risk of blood clots, potentially causing severe pregnancy complications, including pulmonary embolism, hypercoagulability, or miscarriages. Testing for thrombophilia is particularly critical for women with recurrent miscarriages or a family history of blood-clot-related issues.
The test analyzes 50 genetic loci, using an advanced algorithm to calculate the genetic risk for gestational diabetes. This analysis identifies women with twice the risk of developing gestational diabetes compared to women at low genetic risk.
Additionally, the test includes 11 variants related to thrombosis risk (Factor II, FV Leiden, FXIII, β-Fibrinogen, HPA1, MTHFR, ACE, APOB, APOE), enhancing the prediction of thromboembolic events. Results guide preventive treatments such as the use of low-molecular-weight heparin during pregnancy.
Genetic testing provides precise risk evaluation, enabling proactive and personalized healthcare management during pregnancy. By identifying individuals at high genetic risk, targeted interventions can effectively reduce the risk of serious pregnancy complications, safeguarding the health of both mother and baby.
